Double blind, parallel, ramdomised study of two eryaspase formulations in patients with de novo or relapsed acute lymphoblastic leukemia/lymphoma.
Phase of Trial: Phase II
Latest Information Update: 24 Jun 2018
At a glance
- Drugs ERY-ASP (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Pharmacokinetics
- 24 Jun 2018 According to a ERYtech Pharma media release, the company has ceased the development of Eryaspase in Acute Lymphoblastic Leukemia (ALL)including the withdrawal of its European MAA, based on recent feedback from the regulatory agencies in Europe and the United States, which states that, the company would require an additional investment in order to seek regulatory approval of eryaspase for the treatment of ALL.
- 24 Jun 2018 Status changed from recruiting to discontinued, according to a ERYtech Pharma media release.
- 16 Oct 2017 New trial record